Potential impact on blood availability and donor iron status of changes to donor hemoglobin cutoff and interdonation intervals

Transfusion

Volumn 56, Issue 8, 2016, Pages 1994-2004

  Spencer, Bryan R ^a   Johnson, Bryce ^b   Wright, David J ^b   Kleinman, Steven ^c   Glynn, Simone A ^d   Cable, Ritchard G ^a  

^a AMERICAN RED CROSS BLOOD SERVICES   (United States)

^b WESTAT   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; HEMOGLOBIN; IRON;

ADULT; ARTICLE; BLOOD DONOR; ERYTHROCYTE; FEMALE; FERRITIN BLOOD LEVEL; GROUPS BY AGE; HUMAN; IRON BLOOD LEVEL; IRON DEPLETION; MALE; MIDDLE AGED; NORMAL HUMAN; OUTCOME ASSESSMENT; SIMULATION; YOUNG ADULT;

EID: 84982902987     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13663     Document Type: Article

References (14)

1. The 2013 blood collection, utilization, and patient blood management survey report. Bethesda (MD): AABB; 2015.
2. Requirements for blood and blood components intended for transfusion or for further manufacturing use [Internet]. Federal Register, Volume 80 No. 99, 2015 [cited Jan 17, 2016]. Available from: https://federalregister.gov/a/2015-12228.
3. Cable RG, Glynn SA, Kiss JE, et al. Iron deficiency in blood donors: the REDS-II donor iron status evaluation (RISE) study. Transfusion 2012;52:702–11.
4. Cable RG, Glynn SA, Kiss JE, et al. Iron deficiency in blood donors: the REDS-II donor iron status evaluation (RISE) study. Transfusion 2011;51:511–22.
5. Custer B, Bravo M, Bruhn R, et al. Predictors of hemoglobin recovery or deferral in blood donors with an initial successful donation. Transfusion 2014;54:2267–75.
6. Nasserinejad K, van Rosmalen J, de Kort W, et al. Prediction of hemoglobin in blood donors using a latent class mixed-effects transition model. Stat Med 2016;35:581–94.
7. Kiss J, Brambilla D, Glynn SA, et al. Oral iron supplementation after blood donation: a randomized clinical trial. JAMA 2015;6:575–83.
8. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006;107:1747–50.
9. Eder A. Proposed changes to hemoglobin and donation interval criteria for whole blood donors: projected impact on current donor base [Internet]. Paper presented at the 98th meeting of Blood Products Advisory Committee. Gaithersburg (MD). U.S. Food and Drug Administration; 2008 Jul 28 [cited 2013 Dec 23]. Available from: http://www.fda.gov/ohrms/dockets/ac/cber08.html#BloodProducts.
10. Association Bulletin 12-03—Strategies to monitor, limit or prevent iron deficiency in blood donors [Internet]. Bethesda (MD): AABB; 2012 Sep 21 [cited 2016 May 22]. Available from: http://www.aabb.org/programs/publications/bulletins/Pages/ab12-03.aspx.
11. Gandhi MJ, Duffy K, Benike M, et al. Effect of increasing hemoglobin cutoff in male donors and increasing interdonation interval in whole blood donors at a hospital-based blood donor center. Transfusion 2012;52:1880–8.
12. Sayers M, Centilli J. Contemplating the effect on blood availability if the interdonation interval of 56 days is prolonged. Transfusion 2013;53:1132–6.
13. Fowler WM, Barer AP. Rate of hemoglobin regeneration in blood donors. JAMA 1942;118:421–7.
14. Mast AE, Bialkowski W, Bryant BJ, et al. A randomized, blinded, placebo-controlled trial of education and iron supplementation for mitigation of iron deficiency in regular blood donors. Transfusion 2016;56:1588–97.